NFKB1 and systemic lupus erythematosus: These findings collectively demonstrate that LCD ameliorates SLE-associated OP through targeted inhibition of the hyperactivated NF-κB signaling pathway, thereby interrupting the inflammatory cascade that drives bone destruction in SLE (Figure 5).